### 2021-06-21

## **Investigating Top Ranked ERBB2 Related Drugs** Meeting with Dr. Han

- This is repurposing rather than validation, which is off the right track.
    - 药物有脱靶效应
    - 某种inhibitor数据最好只能验证该inhibitor的数据
    - 不能用于ranking the methods
- Method Ranking + Clincial validation
- VAEN clincial data: cox model 
- 看别人的paper
- NPC 

### 2021-06-22
## Met with Qiang
- GR clinical data inhibitor status: only in BRCA data, ERBB2 status, PR status, ER status.   
- [ ] Clinical validation: 9 methods vs. VAEN clinical data vs. COX model
- [ ] Debug VAEN on our data.
- [ ] Read paper x 4.

### 2021-06-24
1. **Apply our methods to clinical datasets VAEN provided**
    - [x] Fig 5. GSE33072 survival analysis and plots: 25 pts vs. 9 methods.
    - [ ] Fig 5. GSE20194 Boxplot only. （需要吗？）
    - [ ] Fig 5. GSE65185 GSE65185_CuffnormFPKM 来源？
    - [ ] Fig 4. TCGA-STAD samples treated with 5-fluorouracil. Survival analysis （需要吗？）
    - KNN, RF 不能用于新数据，改用KKNN，ranger。

    
2. **Paper reading**

### 2021-06-25
1. **Paper reading**
    - *Zhu, Jie, et al. "Prediction of drug efficacy from transcriptional profiles with deep learning." Nature Biotechnology (2021): 1-9.
APA*: 
    - 预测化学结构，lot in the clinical meaning. 不是非常相关
    - Confidencial.  不是非常相关
    - 
2. **Meet with Qiang**
    - Our method w/ VAEN data: RF performs best. Others opposite direction.  
    - Our data w/ VAEN: very different result. 
    - 出现的问题：VAEN和我们的方法都有，model prediction不同的data给完全一样的结果，导致VAEN model数量很少，导致我们的RF和KNN不能predict新数据。
        - 从code方向没有找到解决办法
        - 输入文件？CCLE RNAseq expression data RPKM (我们2019 VAEN2018). GDSC 
        - Ask Dr. Han.
    - Original: 25100 model Our data: less than 8000 model. -> Empty model. for some 
    - 
    - [ ] Our method repeat VAEN Fig. 4B.
    - [ ] Review VAEN code. 
    - [ ] 补validation。
    - [ ] 想法：有没有可能其实是有10套validation，选了对自己最有利的？
    - [ ] 要把validation做到全面滴水不漏 is not simple.
    - [ ] ？输入文件？导致结果完全相反
    - [ ] ？test data set？只用一套讲故事是有特殊性的，GR和VAEN都用了，结果差很多。
    - [ ] 找inhibitor clinical data。
    - [ ] Literature review on method comparison.
 

# ================================================
### To-do list last week:
- [x] Discussion on Top Ranked ERBB2 Related Drugs.
- [ ] Evaluate VAEN using statistical mesaurements and compare with our methods.
- [x] Apply our methods to clinical datasets VAEN provided.
    * Current method: Divide pts based on the median of predicted result. Conduct survival analysis between 2 groups. Compare p value (smaller better).
    * Come up with other method.
    * Potential idea: correlation between GEO progression-free survival time and predicted response. Higher R2 better. Use prediction as continuous rather than binary.
- [ ] Literature review and discussion: 
    * Finish reading shared articles. 
    * How to tell which method is the best?
  
